Bioconjugate development continues to be a markedly complex proposition for drug developers, driven, in part, by increasingly intricate, disparate supply chains and a pervasive lack of expertise across the biotherapeutic sector. Iwan Bertholjotti, Director of Commercial Development of Bioconjugates, and Dr. Bernhard Stump, Head of Development of Bioconjugates, recently hosted  a Q&A session after their webinar The Challenges of Moving a Bioconjugate Candidate from Clinic to Market. Here you can read  the questions they addressed from attendees regarding Lonza’s expertise and history in this space.

Latest content

Latest briefing from the Knowledge Center